Sunitinib Malate: Clinical Trials

95 trials of Sunitinib Malate, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

58 completed, 21 terminated, 7 unknown, 6 active not recruiting. 95 Phase 2, 8 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 295Completed 58, Terminated 21, Unknown 7, Active not recruiting 6, Withdrawn 3
Phase 18Terminated 4, Completed 2, Unknown 2
Phase 32Completed 1, Unknown 1

Follow Sunitinib Malate: new trials by email Literature Review of Sunitinib Malate trials Research Report on Sunitinib Malate

Trials (filtered) newest first · largest first

All 95 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
Sunitinib Malate, TAS 102 - Colorectal Cancer, Metastasis
Phase 2 / Phase 3UnknownAmsterdam UMC, location VUmc602019-10-012020-11-13
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Drug: GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration
Phase 2CompletedGraybug Vision562019-09-262022-01-19
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
GB-102 - Diabetic Macular Edema, Retina Vein Occlusion
Phase 2CompletedGraybug Vision212019-09-112021-11-22
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate - Thymic Carcinoma
Phase 2Active not recruitingDwight Owen92018-06-192026-08-06
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
Cabozantinib, Sunitinib Malate - Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center322018-05-152026-07-16
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)1522016-07-252025-01-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)64522015-08-172026-11-12
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Sunitinib malate - Renal Cell Carcinoma
Phase 2Terminatedvghtpe user132015-08-122018-06-26
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Sunitinib, Valproic Acid, Sunitinib Malate - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Phase 2Active not recruitingSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University2102014-11-192026-10-22
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
Sunitinib, Questionnaire - Genitourinary Cancer, Kidney Cancer
Phase 2CompletedM.D. Anderson Cancer Center602014-08-012020-02-27
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate - Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)1572013-07-082021-02-11
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate - Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)412012-08-012022-06-07
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
sunitinib malate dose escalation, sunitinib malate - Gastrointestinal Stromal Tumors
Phase 2CompletedPfizer62012-06-012019-03-27
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Antitumor Drug Screening Assay, Dasatinib, Idelalisib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Phase 2TerminatedOHSU Knight Cancer Institute122012-05-112021-11-04
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate - Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma
Phase 2CompletedNational Cancer Institute (NCI)302012-01-012015-08-27
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
Abiraterone Acetate, Prednisone, Sunitinib - Prostate Cancer
Phase 2CompletedM.D. Anderson Cancer Center1902011-03-162025-01-27
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
Dacarbazine, Sunitinib - Metastatic Uveal Melanoma
Phase 2CompletedThe Clatterbridge Cancer Centre NHS Foundation Trust1242010-10-012019-10-29
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
sunitinib malate - Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Phase 2CompletedCase Comprehensive Cancer Center372010-08-182018-09-14
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
Everolimus, Sunitinib - Kidney Cancer
Phase 2TerminatedM.D. Anderson Cancer Center732010-08-012021-04-28
Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
sunitinib malate, Placebo, transarterial chemoembolization - Liver Cancer
Phase 2 / Phase 3CompletedFederation Francophone de Cancerologie Digestive782010-07-012022-03-18

Showing 20 of 95. Sign in to see all of them.

Conditions studied

Carcinoma, Renal Cell (24)  ·  Kidney Neoplasms (13)  ·  Breast Neoplasms (7)  ·  Neoplasm Metastasis (7)  ·  Urinary Bladder Neoplasms (7)  ·  Prostatic Neoplasms (6)  ·  Carcinoma, Hepatocellular (5)  ·  Esophageal Neoplasms (4)  ·  Liver Neoplasms (4)  ·  Melanoma (4)  ·  Ovarian Neoplasms (4)  ·  Uveal Melanoma (4)  ·  Astrocytoma (3)  ·  Brain Neoplasms (3)  ·  Breast Neoplasms, Male (3)

Sponsors

National Cancer Institute (NCI) (23)  ·  M.D. Anderson Cancer Center (9)  ·  Case Comprehensive Cancer Center (5)  ·  Memorial Sloan Kettering Cancer Center (5)  ·  H. Lee Moffitt Cancer Center and Research Institute (3)  ·  Pfizer (3)  ·  University of Washington (3)  ·  Federation Francophone de Cancerologie Digestive (2)  ·  Graybug Vision (2)  ·  OHSU Knight Cancer Institute (2)  ·  US Oncology Research (2)  ·  University of California, San Francisco (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Amsterdam UMC, location VUmc (1)

Countries

United States (70)  ·  Canada (10)  ·  France (6)  ·  United Kingdom (4)  ·  Australia (3)  ·  Netherlands (2)  ·  South Korea (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Czechia (1)  ·  Guam (1)  ·  Italy (1)  ·  Mexico (1)

Top investigators

Eric Jonasch, MD (3)  ·  Robert J. Motzer, MD (3)  ·  Amado Zurita, MD (2)  ·  Dean F. Bajorin, MD (2)  ·  Hope S. Rugo, MD (2)  ·  Jonathan Strosberg, MD (2)  ·  Alain Ravaud, MD, PhD (1)  ·  Aminah Jatoi, MD (1)  ·  Amit M Oza (1)  ·  Arkadiusz Dudek, MD (1)  ·  Brian I. Rini, MD (1)  ·  Brian Rini (1)  ·  Catherine Meyerle, MD (1)

Results publications

PMID 33852135, PMID 37146227, PMID 19451429, PMID 19536893, PMID 19547919, PMID 20203173, PMID 20711632, PMID 20975250, PMID 21148613, PMID 21174224, PMID 21898376, PMID 22105611, PMID 22261812, PMID 22425095, PMID 22614181, PMID 22761653, PMID 23228446, PMID 23660867, PMID 24268852, PMID 24821582, PMID 24882554, PMID 25085632, PMID 25532471, PMID 25577718, PMID 25732163, PMID 25802238, PMID 26151457, PMID 26582660, PMID 26586415, PMID 27029034, PMID 27109549, PMID 27217543, PMID 27238653, PMID 28410911, PMID 28549224, PMID 29550566, PMID 29641297, PMID 29921512, PMID 31006038, PMID 31231785, PMID 31371341, PMID 31399500, PMID 31986451, PMID 32463741, PMID 32576496, PMID 32623479, PMID 33048619, PMID 33592176, PMID 34393061, PMID 35133871

NIH funding

P30CA008748 (4), U10CA031946 (4), N01CM62201 (3), N01CM62203 (3), P30CA043703 (3), U10CA180821 (3), N01CM62202 (2), P30CA014599 (2), U10CA027469 (2), 2008 (1), N01CM00038 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1), N01CM62209 (1)